Carbon nanomaterials: a new way against tuberculosis

References

• Lönnroth K, Migliori GB, Abubakar I, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45:928–952.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tubercolosis report 2017. 2017.
   Google Scholar
• Dheda K, Migliori GB. The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? Lancet. 2012;379:773–775.
   PubMed Web of Science ®Google Scholar
• Lange C, Chesov D, Heyckendorf J, et al. Drug‐resistant tuberculosis: an update on disease burden, diagnosis and treatment. Respirology. 2018;23:656–673.
   PubMed Web of Science ®Google Scholar
• Delogu G, Sali M, Fadda G. The biology of mycobacterium tuberculosis infection. Mediterr J Hematol Infect Dis. 2013;1:5.
   Google Scholar
• Neyrolles O, Hernández-Pando R, Pietri-Rouxel F, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One. 2006;1:e43.
   PubMed Web of Science ®Google Scholar
• Gengenbacher M, Kaufmann SHE. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev. 2012;36:514–532.
   PubMed Web of Science ®Google Scholar
• Peddireddy V, Doddam SN, Ahmed N. Mycobacterial dormancy systems and host responses in tuberculosis. Front Immunol. 2017;8:84.
   PubMed Web of Science ®Google Scholar
• Russell DG, Cardona P-J, Kim M-J, et al. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol. 2009;10:943.
   PubMed Web of Science ®Google Scholar
• WHO. Treatment of tuberculosis: guidelines. World Health Organization; 2010. Available from: https://www.who.int/tb/publications/2010/9789241547833/en/
   Google Scholar
• Traini D, Young PM. Drug delivery for tuberculosis: is inhaled therapy the key to success?. Future Sci Ther Deliv. 2017;8(10):819–821.
   Google Scholar
• Mohajeri M, Behnam B, Sahebkar A. Biomedical applications of carbon nanomaterials: drug and gene delivery potentials. J Cell Physiol. 2019;234:298–319.
   Web of Science ®Google Scholar
• Di Santo R, Digiacomo L, Palchetti S, et al. Microfluidic manufacturing of surface-functionalized graphene oxide nanoflakes for gene delivery. Nanoscale. 2019;11:2733–2741.
   PubMed Web of Science ®Google Scholar
• Di Santo R, Quagliarini E, Palchetti S, et al. Microfluidic-generated lipid-graphene oxide nanoparticles for gene delivery. Appl Phys Lett. 2019;114:233701.
   Web of Science ®Google Scholar
• Liu J, Cui L, Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. [Internet] 2013;9:9243–9257.
   PubMed Web of Science ®Google Scholar
• Palmieri V, Barba M, Di Pietro L, et al. Reduction and shaping of graphene-oxide by laser-printing for controlled bone tissue regeneration and bacterial killing. 2D Mater. 2018;5:015027.
   Google Scholar
• Sharma P, Kumar Mehra N, Jain K, et al. Biomedical applications of carbon nanotubes: a critical review. Curr Drug Deliv. 2016;13:796–817.
   PubMed Web of Science ®Google Scholar
• Papi M, Palmieri V, Digiacomo L, et al. Converting the personalized biomolecular corona of graphene oxide nanoflakes into a high-throughput diagnostic test for early cancer detection. Nanoscale. 2019;11(32):15339–15346.
   Web of Science ®Google Scholar
• Hosnedlova B, Kepinska M, Fernandez C, et al. Carbon nanomaterials for targeted cancer therapy drugs: A critical review. Chem Rec. 2019;19:502–522.
   PubMed Web of Science ®Google Scholar
• Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J Rheumatol Suppl. 2014;91:11–16.
   PubMedGoogle Scholar
• Lange C, Chesov D, Furin J, et al. Revising the definition of extensively drug-resistant tuberculosis. Lancet Respir Med. 2018;6:893–895.
   PubMed Web of Science ®Google Scholar
• Abbasi MA. Guidelines for the treatment of drug resistant tuberculosis: the 2018 revision. J Ayub Med Coll Abbottabad. 2018;30:493–494.
   PubMedGoogle Scholar
• Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360:2397–2405.
   PubMed Web of Science ®Google Scholar
• Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366:2151–2160.
   PubMed Web of Science ®Google Scholar
• Organization WH. WHO consolidated guidelines on drug-resistant tuberculosis treatment. 2019. Available from: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/
   Google Scholar
• Dickinson JM, Aber VR, Mitchison DA. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis. 1977;116:627–635.
   PubMed Web of Science ®Google Scholar
• GF F, Dos S, Salgado HRN, et al. Isoniazid: a review of characteristics, properties and analytical methods. Crit Rev Anal Chem. 2017;47:298–308.
   PubMed Web of Science ®Google Scholar
• Zenner D, Beer N, Harris RJ, et al. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167:248–255.
   PubMed Web of Science ®Google Scholar
• Gülbay BE, ÖU G, ÖA Y, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med. 2006;100:1834–1842.
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–1477.
   PubMed Web of Science ®Google Scholar
• Rachow A, Ivanova O, Wallis R, et al. TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB–a study protocol. BMC Pulm Med. 2019;19:4.
   PubMed Web of Science ®Google Scholar
• Xu K, Liang ZC, Ding X, et al. Nanomaterials in the prevention, diagnosis, and treatment of mycobacterium tuberculosis infections. Adv Healthc Mater. 2018;7:1700509.
   Web of Science ®Google Scholar
• Palmieri V, Perini G, De Spirito M, et al. Graphene oxide touches blood: in vivo interactions of bio-coronated 2D materials. Nanoscale Horiz. 2019;273–290. Available from: http://pubs.rsc.org/en/Content/ArticleLanding/2018/NH/C8NH00318A.
   Web of Science ®Google Scholar
• Papi M, Caracciolo G. Principal component analysis of personalized biomolecular corona data for early disease detection. Nano Today. 2018;21:14–17.
   Web of Science ®Google Scholar
• Weiss G, Schaible UE. Macrophage defense mechanisms against intracellular bacteria. Immunol Rev. 2015;264:182–203.
   PubMed Web of Science ®Google Scholar
• Garg T, Rath G, Goyal AK. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis. Cells Nanomed Biotechnol. 2016;44:997–1001.
   PubMed Web of Science ®Google Scholar
• R V P, Jain RR, Bannalikar AS, et al. Development and evaluation of chitosan microparticles based dry powder inhalation formulations of rifampicin and rifabutin. J Aerosol Med Pulm Drug Deliv. 2016;29:179–195.
   PubMed Web of Science ®Google Scholar
• Fenaroli F, Westmoreland D, Benjaminsen J, et al. Nanoparticles as drug delivery system against tuberculosis in zebrafish embryos: direct visualization and treatment. ACS Nano. 2014;8:7014–7026.
   PubMed Web of Science ®Google Scholar
• Suarez S, O’hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 2001;18:1315–1319.
   PubMed Web of Science ®Google Scholar
• Suarez S, O’hara P, Kazantseva M, et al. Airways delivery of rifampicin microparticles for the treatment of tuberculosis. J Antimicrob Chemother. 2001;48:431–434.
   PubMed Web of Science ®Google Scholar
• Doan TVP, Olivier JC. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. Int J Pharm. 2009;382:61–66.
   PubMed Web of Science ®Google Scholar
• Dutt M, Khuller GK. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. J Antimicrob Chemother. 2001;47:829–835.
   PubMed Web of Science ®Google Scholar
• Dutt M, Khuller GK. Therapeutic efficacy of poly (DL-lactide-co-glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother. 2001;45:363–366.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Kabasawa T, Ozeki T, et al. One-step preparation of rifampicin/poly (lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release. 2009;135:19–24.
   PubMed Web of Science ®Google Scholar
• Sung JC, Padilla DJ, Garcia-Contreras L, et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res. 2009;26:1847–1855.
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma A, Zahoor A, et al. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52:981–986.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Nanoparticle-based oral drug delivery system for an injectable antibiotic–streptomycin. Chemotherapy. 2007;53:437–441.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. J Antimicrob Chemother. 2006;57:1146–1152.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother. 2004;54:266–268.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54:761–766.
   PubMed Web of Science ®Google Scholar
• Kumar G, Sharma S, Shafiq N, et al. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv. 2011;18:65–73.
   PubMed Web of Science ®Google Scholar
• Sharma R, Saxena D, Dwivedi AK, et al. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm Res. 2001;18:1405–1410.
   PubMed Web of Science ®Google Scholar
• Verma RK, Kaur J, Kumar K, et al. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother. 2008;52:3195–3201.
   PubMed Web of Science ®Google Scholar
• Muttil P, Kaur J, Kumar K, et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32:140–150.
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Gupta P, Gupta UD, et al. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm. 2010;385:143–149.
   PubMed Web of Science ®Google Scholar
• Zahoor A, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005;26:298–303.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Pandey R, Sharma S, et al. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci. 2006;48:171.
   PubMedGoogle Scholar
• Hwang SM, Kim DD, Chung SJ, et al. Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis. J Control Release. 2008;129:100–106.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Kandpal H, Gupta HP, et al. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob Agents Chemother. 1994;38:588–593.
   PubMed Web of Science ®Google Scholar
• Wu T, Liao W, Wang W, et al. Genipin-crosslinked carboxymethyl chitosan nanogel for lung-targeted delivery of isoniazid and rifampin. Carbohydr Polym. 2018;197:403–413.
   Web of Science ®Google Scholar
• Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother. 1997;41:1211–1214.
   PubMed Web of Science ®Google Scholar
• Labana S, Pandey R, Sharma S, et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents. 2002;20:301–304.
   PubMed Web of Science ®Google Scholar
• Takenaga M, Ohta Y, Tokura Y, et al. Lipid microsphere formulation containing rifampicin targets alveolar macrophages. Drug Deliv. 2008;15:169–175.
   PubMed Web of Science ®Google Scholar
• Das AR, Dattagupta N, Sridhar CN, et al. The use of rifampicin and isoniazid entrapped in liposomes for the treatment of murine tuberculosis. Scand J Infect Dis. 1986;35:168–174.
   Google Scholar
• El-Ridy MS, Mostafa DM, Shehab A, et al. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm. 2007;330:82–88.
   PubMed Web of Science ®Google Scholar
• Gaspar MM, Cruz A, Penha AF, et al. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents. 2008;31:37–45.
   PubMed Web of Science ®Google Scholar
• Dhillon J, Fielding R, Adler-Moore J, et al. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J Antimicrob Chemother. 2001;48:869–876.
   PubMed Web of Science ®Google Scholar
• Whitehead TC, Lovering AM, Cropley IM, et al. Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 1998;17:794–797.
   PubMed Web of Science ®Google Scholar
• Adams LB, Sinha I, Franzblau SG, et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother. 1999;43:1638–1643.
   PubMed Web of Science ®Google Scholar
• Deol P, Khuller GK. Lung specific stealth liposomes : stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta. 1997;1334(2-3):161–172.
   Google Scholar
• Singh J, Garg T, Rath G, et al. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuber-culosis – a critical review. Drug Deliv. 2016;23(5):1676–1698.
   Google Scholar
• El-ridy MS, Yehia SA, Kassem MA, et al. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety. Drug Deliv. 2015;22(1):21–36.
   Google Scholar
• Jain CP, Vyasand SP, Dixit VK. Niosomal system for delivery of rifampicin to lymphatics. Indian J Pharm Sci. 2006;68(5):575–578.
   Google Scholar
• Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 2015;5:305.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 2005;85:227–234.
   PubMed Web of Science ®Google Scholar
• Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm. 2013;441:202–212.
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis. 2005;85:415–420.
   PubMed Web of Science ®Google Scholar
• Nimje N, Agarwal A, Saraogi GK, et al. Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting. J Drug Target. 2009;17:777–787.
   PubMed Web of Science ®Google Scholar
• Saraogi GK, Sharma B, Joshi B, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis. J Drug Target. 2011;19:219–227.
   PubMed Web of Science ®Google Scholar
• Bhardwaj A, Kumar L, Narang RK, et al. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis. Cells Nanomed Biotechnol. 2013;41:52–59.
   PubMed Web of Science ®Google Scholar
• Greco E, Quintiliani G, Santucci MB, et al. Janus-faced liposomes enhance antimicrobial innate immune response in Mycobacterium tuberculosis infection. Proc Natl Acad Sci. 2012;109(21):E1360-8.
   PubMedGoogle Scholar
• Dasari Shareena TP, McShan D, Dasmahapatra AK, et al. A review on graphene-based nanomaterials in biomedical applications and risks in environment and health. Nano-Micro Lett. [Internet]. 2018;10:1–34.
   PubMed Web of Science ®Google Scholar
• Maiti D, Tong X, Mou X, et al. Carbon-based nanomaterials for biomedical applications: a recent study. Front Pharmacol. 2018;9:1401.
   PubMed Web of Science ®Google Scholar
• Al-Jumaili A, Alancherry S, Bazaka K, et al. Review on the antimicrobial properties of carbon nanostructures. Materials (Basel). 2017;10:1066.
   PubMed Web of Science ®Google Scholar
• Giubileo F, Di Bartolomeo A, Iemmo L, et al. Field emission from carbon nanostructures. Appl Sci. 2018;8:526.
   Google Scholar
• Palmieri V, Bugli F, Lauriola MC, et al. Bacteria meet graphene: modulation of graphene oxide nanosheet interaction with human pathogens for effective antimicrobial therapy. ACS Biomater Sci Eng. 2017;3:619–627.
   Web of Science ®Google Scholar
• Bosi S, Da Ros T, Castellano S, et al. Antimycobacterial activity of ionic fullerene derivatives. Bioorg Med Chem Lett. 2000;10:1043–1045.
   PubMed Web of Science ®Google Scholar
• Saikia N, Rajkhowa S, Deka RC. Density functional and molecular docking studies towards investigating the role of single-wall carbon nanotubes as nanocarrier for loading and delivery of pyrazinamide antitubercular drug onto pncA protein. J Comput Aided Mol Des. 2013;27:257–276.
   PubMed Web of Science ®Google Scholar
• Pramanik S, Konwarh R, Barua N, et al. Bio-based hyperbranched poly (ester amide)–MWCNT nanocomposites: multimodalities at the biointerface. Biomater Sci. 2014;2:192–202.
   Web of Science ®Google Scholar
• Palmieri V, Lauriola MC, Ciasca G, et al. The graphene oxide contradictory effects against human pathogens. Nanotechnology. 2017;28:152001.
   PubMed Web of Science ®Google Scholar
• Jing H, Sahle-Demessie E, Sorial GA. Inhibition of biofilm growth on polymer-MWCNTs composites and metal surfaces. Sci Total Environ. 2018;633:167–178.
   PubMed Web of Science ®Google Scholar
• Palmieri V, Bugli F, Cacaci M, et al. Graphene oxide coatings prevent Candida albicans biofilm formation with a controlled release of curcumin-loaded nanocomposites. Nanomedicine. 2018;13:2867–2879.
   PubMed Web of Science ®Google Scholar
• Bugli F, Cacaci M, Palmieri V, et al. Curcumin-loaded graphene oxide flakes as an effective antibacterial system against methicillin-resistant Staphylococcus aureus. Interface Focus. 2018;8:20170059.
   PubMed Web of Science ®Google Scholar
• Park E-J, Lee G-H, Han BS, et al. Toxic response of graphene nanoplatelets in vivo and in vitro. Arch Toxicol. 2015;89:1557–1568.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yin J, Peng C, et al. Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration. Carbon N Y. 2011;49:986–995.
   Web of Science ®Google Scholar
• Liu J-H, Wang T, Wang H, et al. Biocompatibility of graphene oxide intravenously administrated in mice—effects of dose, size and exposure protocols. Toxicol Res (Camb). 2015;4:83–91.
   Web of Science ®Google Scholar
• Zou F, Zhou H, Jeong DY, et al. Wrinkled surface-mediated antibacterial activity of graphene oxide nanosheets. ACS Appl Mater Interfaces. 2017;9:1343–1351.
   PubMed Web of Science ®Google Scholar
• De Maio F, Palmieri V, Salustri A, et al. Graphene oxide prevents mycobacteria entry in macrophages through extracellular entrapment. Nanoscale Adv. 2019;1:1421–1431 .
   Web of Science ®Google Scholar
• Papi M, Palmieri V, Bugli F, et al. Biomimetic antimicrobial cloak by graphene-oxide agar hydrogel. Sci Rep. 2016;6:12.
   PubMedGoogle Scholar
• Palmieri V, Papi M, Conti C, et al. The future development of bacteria fighting medical devices: the role of graphene oxide. Expert Rev Med Devices. 2016;13:1013–1019.
   PubMed Web of Science ®Google Scholar
• Palmieri V, Dalchiele EA, Perini G, et al. Biocompatible N-acetyl cysteine reduces graphene oxide and persists at the surface as a green radical scavenger. Chem Commun. [Internet]. 2019;55:4186–4189. DOI:10.1039/C9CC00429G.
   PubMed Web of Science ®Google Scholar
• Han W, Niu W-Y, Sun B, et al. Biofabrication of polyphenols stabilized reduced graphene oxide and its anti-tuberculosis activity. J Photochem Photobiol B Biol. 2016;165:305–309.
   PubMed Web of Science ®Google Scholar
• More MP, R V C, Bhadane MS, et al. Development of graphene-drug nanoparticle based supramolecular self assembled pH sensitive hydrogel as potential carrier for targeting MDR tuberculosis. Mater Technol. 2019;34:324–335.
   Web of Science ®Google Scholar
• Saifullah B, Maitra A, Chrzastek A, et al. Nano-formulation of ethambutol with multifunctional graphene oxide and magnetic nanoparticles retains its anti-tubercular activity with prospects of improving chemotherapeutic efficacy. Molecules. 2017;22:1697.
   Web of Science ®Google Scholar
• Saifullah B, Chrzastek A, Maitra A, et al. Novel anti-tuberculosis nanodelivery formulation of ethambutol with graphene oxide. Molecules. 2017;22:1560.
   PubMed Web of Science ®Google Scholar
• Moradi S, Taran M, Mohajeri P, et al. Study of dual encapsulation possibility of hydrophobic and hydrophilic drugs into a nanocarrier based on bio-polymer coated graphene oxide using density functional theory, molecular dynamics simulation and experimental methods. J Mol Liq. 2018;262:204–217.
   Web of Science ®Google Scholar
• Tudose M, Anghel EM, Culita DC, et al. Covalent coupling of tuberculostatic agents and graphene oxide: A promising approach for enhancing and extending their antimicrobial applications. Appl Surf Sci. 2019;471:553–565.
   Web of Science ®Google Scholar
• Bogdanović G, Djordjević A. Carbon nanomaterials: biologically active fullerene derivatives. Srp Arh Celok Lek. 2016;144:222–231.
   PubMed Web of Science ®Google Scholar
• Ou L, Song B, Liang H, et al. Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms. Part Fibre Toxicol. 2016;13:57.
   PubMed Web of Science ®Google Scholar
• Khalid P, Hussain MA, Suman VB, et al. Toxicology of carbon nanotubes-a review. Int J Appl Eng Res. 2016;11:148–157.
   Google Scholar
• Palmieri V, Barba M, Di Pietro L, et al. Graphene oxide induced osteogenesis quantification by in-situ 2D-fluorescence spectroscopy. Int J Mol Sci. 2018;19:3336.
   Web of Science ®Google Scholar
• Vlăsceanu GM, Iovu H, Ioniţă M. Graphene inks for the 3D printing of cell culture scaffolds and related molecular arrays. Compos B Eng. 2019;162:712–723.
   Web of Science ®Google Scholar
• Lee DY, Khatun Z, Lee J-H, et al. Blood compatible graphene/heparin conjugate through noncovalent chemistry. Biomacromolecules. 2011;12:336–341.
   PubMed Web of Science ®Google Scholar
• Neoh KG, Hu X, Zheng D, et al. Balancing osteoblast functions and bacterial adhesion on functionalized titanium surfaces. Biomaterials. 2012;33:2813–2822.
   PubMed Web of Science ®Google Scholar
• Engberg AE, Nilsson PH, Huang S, et al. Prediction of inflammatory responses induced by biomaterials in contact with human blood using protein fingerprint from plasma. Biomaterials. 2015;36:55–65.
   PubMed Web of Science ®Google Scholar
• Ferrari AC, Bonaccorso F, Fal’Ko V, et al. Science and technology roadmap for graphene, related two-dimensional crystals, and hybrid systems. Nanoscale. 2015;7:4598–4810.
   PubMed Web of Science ®Google Scholar
• Wick P, Louw‐Gaume AE, Kucki M, et al. Classification framework for graphene‐based materials. Angew Chemie Int Ed. 2014;53:7714–7718.
   PubMed Web of Science ®Google Scholar
• Reina G, González-Domínguez JM, Criado A, et al. Promises, facts and challenges for graphene in biomedical applications. Chem Soc Rev. 2017;46:4400–4416.
   PubMed Web of Science ®Google Scholar